am 251 has been researched along with Amphetamine-Related Disorders in 2 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Amphetamine-Related Disorders: Disorders related or resulting from use of amphetamines.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nawata, Y | 1 |
| Kitaichi, K | 1 |
| Yamamoto, T | 1 |
| Vinklerová, J | 1 |
| Nováková, J | 1 |
| Sulcová, A | 1 |
2 other studies available for am 251 and Amphetamine-Related Disorders
| Article | Year |
|---|---|
Prevention of drug priming- and cue-induced reinstatement of MDMA-seeking behaviors by the CB1 cannabinoid receptor antagonist AM251.
Topics: Amphetamine-Related Disorders; Animals; Cannabinoid Receptor Antagonists; Cues; Dose-Response Relati | 2016 |
Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251.
Topics: Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Conditioning, Operant; Do | 2002 |